Payer Pushback Underpins Mallinckrodt's Disappointing Q3 Results
Executive Summary
Mallinckrodt's high-priced H.P Acthar Gel was under pressure in the third quarter, which management attributed to payer complexities. The issue is broader than just Acthar, firm says.
You may also be interested in...
MedPAC Analysis Of 'Low-Value' Medicare Treatments Spotlights Acthar
The Medicare Payment Advisory Commission’s annual 2018 report to Congress features the flip side of the recent value-based rhetoric – highlighting “low-value” Medicare purchases. The drug chosen to make that argument is Mallinckrodt’s HP Acthar Gel.
Stock Scan November 2017: Generics get volatile
Generic drug producers endured very mixed fortunes on the world's stock markets, with firms ending November at opposite ends of Scrip's Stock Scan monthly league table.
Mallinckrodt Looks To Increase Hospital Product Offerings With Questcor Purchase
Less than a year after its spinout, Mallinckrodt has announced its second large acquisition, paying $5.6 billion for Questcor and its potential blockbuster product.